| 生物活性 |
Viridicatol is a quinolone alkaloid possessing anti-inflammatory, antibacterial, antifungal, osteogenic, and chondrogenic activities that reduces the phosphorylation levels of ERK, JNK, p38, and STAT6, inhibits MMP-2, MMP-9, the NF-κB signaling pathway, and PTP1B, downregulates mast cell activation-related genes, and binds SHN3 to activate the Wnt/SHN3 signaling pathway, thereby suppressing the expression of pro-inflammatory mediators and cytokines and promoting osteogenic/chondrogenic differentiation, and can be used in research related to fibrosarcoma, allergy, bacterial infection, fungal infection, and osteoporosis. |
体外研究 (In Vitro) |
Viridicatol (10-100 μM; 24 h) 对 HT1080 人纤维肉瘤细胞在 10、20 和 50 μM 浓度下无细胞毒性,但在 100 μM 浓度下可诱导细胞毒性。 Viridicatol (10-50 μM; 1 h pre-incubation, followed by 24 h PMA stimulation) 抑制 HT1080 人纤维肉瘤细胞中 PMA 诱导的 MMP-2 和 MMP-9 酶活性。 Viridicatol (10-50 μM; 1 h pre-incubation, followed by 24 h PMA stimulation) 可降低 HT1080 人纤维肉瘤细胞中 PMA 诱导的 MMP-2 蛋白表达,但不影响 MMP-9 蛋白表达。 Viridicatol (10-50 μM; 1 h pre-incubation, followed by 24 h PMA stimulation) 抑制 HT1080 人纤维肉瘤细胞中 PMA 诱导的 ERK、JNK 和 p38 磷酸化。 Viridicatol (10 μg/mL; 1 h pre-incubation prior to 1 h DNP-BSA stimulation) 可在 IgE 介导激活的 RBL-2H3 细胞中调控 128 个差异表达基因,主要下调肥大细胞激活相关的炎症因子和趋化因子基因。 Viridicatol (10 μg/mL; 1 h pre-incubation prior to 1 h DNP-BSA stimulation) 可显著下调 IgE 介导激活的 RBL-2H3 细胞中肥大细胞活化相关基因 (Tnfα、Ccl2、Jun、Fos、Il4、Ccl7、Il13 及 Socs1) 的表达。 Viridicatol (2.5-10 μg/mL; 1 h pre-incubation prior to 15 min DNP-BSA stimulation) 可剂量依赖性地抑制 IgE 介导激活的 RBL-2H3 细胞中 JNK、ERK、P38 和 STAT6 蛋白的磷酸化,从而抑制 MAPK 和 JAK-STAT 通路的激活。 Viridicatol (compound 2) (0.98-500 μg/mL; 1 day) 对金黄色葡萄球菌 (MIC = 15.6 μg/mL) 表现出强效抗菌活性,对大肠杆菌、铜绿假单胞菌、乳酸链球菌、胶孢炭疽菌和禾谷镰孢菌表现出中等活性。 Viridicatol (0.98-500 μg/mL; 2 days) 对 Alternaria brassicae、Botrytis cinerea 和 Valsa mali 表现出强效抗真菌活性 (MIC = 31.2 μg/mL),对链格孢、玉米大斑病菌、核盘菌、辣椒疫霉和牡丹炭疽表现出中等活性。 Viridicatol (compound 1) (5-160 μM; 24 h) 对 RAW264.7 和 BV2 细胞无细胞毒性。 Viridicatol (10-80 μM; 3 h pre-treatment, followed by 24 h LPS stimulation) 可剂量依赖性地抑制 LPS 刺激的 RAW264.7 细胞中促炎介质的产生及相关蛋白的表达,其中 NO 的 IC50 值为 46.03 μM,PGE2 的 IC50 值为 30.37 μM。 Viridicatol (10-80 μM; 3 h pre-treatment, followed by 24 h LPS stimulation) 可剂量依赖性地抑制 LPS 刺激的 BV2 细胞中促炎介质的产生及相关蛋白的表达,其中 NO 的 IC50 值为 43.03 μM,PGE2 的 IC50 值为 34.20 μM。 Viridicatol (10-80 μM; 3 h pre-treatment, followed by 6 h LPS stimulation) 可差异性抑制 LPS 激活的 RAW264.7 细胞与 BV2 细胞中的炎症基因表达。 Viridicatol (10-80 μM; 3 h pre-treatment, followed by 1 h LPS stimulation) 可通过阻断 IκB-α 的磷酸化/降解、NF-κB p65/p50 的核转位及 NF-κB 的 DNA 结合活性,抑制 LPS 刺激的 RAW264.7 和 BV2 细胞中的 NF-κB 信号通路。 Viridicatol (1-10 μM; 5 days) 可促进 MC3T3-E1 前成骨细胞的早期成骨分化,处理 5 天后碱性磷酸酶活性呈浓度依赖性升高可证明这一点。 Viridicatol (1-20 μM; 21 days) 可促进 MC3T3-E1 成骨前体细胞的晚期成骨矿化,处理 21 天后的 EC50 为 5.204 μM。 Viridicatol (1-20 μM; 14 days) 可促进小鼠骨髓来源间充质干细胞的成骨矿化,处理 14 天后其 EC50 为 4.132 μM。 Viridicatol (1-10 μM; ~21 days) 处理约 21 天后,可呈浓度依赖性促进小鼠骨髓来源间充质干细胞的软骨分化。 Viridicatol (5 μM; 0-48 h, 3 days, 5 days, 8 days) 可时间依赖性地抑制 MC3T3-E1 前成骨细胞中 Hivep3 mRNA 的表达,并上调成骨标记基因 Alpl 和 Bglap 的表达。 Viridicatol (5 μM; 8 days) 可促进野生型小鼠骨髓间充质干细胞的成骨矿化,但该作用依赖于 SHN3 的存在。 Viridicatol (1-10 μM; 5 days) 可通过上调 β-catenin、p-GSK-3β 和 p-ERK1/2 的表达并抑制 SHN3 蛋白表达,激活 MC3T3-E1 前成骨细胞中的 Wnt/SHN3 信号通路。 Viridicatol (1-10 μM; 5 days, 5 μM; 3-8 days) 可上调小鼠骨髓间充质干细胞中骨钙蛋白和 β-catenin 蛋白的表达水平。
Cell Viability Assay
| Cell Line: |
HT1080 human fibrosarcoma cells |
| Concentration: |
10 μM, 20 μM, 50 μM, 100 μM |
| Incubation Time: |
24 h |
| Result: |
Showed no obvious cytotoxic effect at 10, 20, and 50 μM. Caused clear cytotoxicity at 100 μM. |
Western Blot Analysis
| Cell Line: |
HT1080 human fibrosarcoma cells |
| Concentration: |
10 μM, 20 μM, 50 μM |
| Incubation Time: |
1 h pre-incubation, followed by 24 h PMA stimulation |
| Result: |
Significantly inhibited MMP-2 protein expression in a dose-dependent manner. Had no inhibitory effect on MMP-9 protein expression in PMA-stimulated cells.\n Dose-dependently reduced the phosphorylation of ERK, JNK, and p38 in PMA-stimulated cells. Showed significant inhibition at all tested concentrations for each MAPK subtype. |
Real Time qPCR
| Cell Line: |
IgE-mediated activated RBL-2H3 cells |
| Concentration: |
10 μg/mL |
| Incubation Time: |
1 h (pre-incubation prior to 1 h DNP-BSA stimulation) |
| Result: |
Significantly down-regulated the mRNA expression levels of Tnfα, Ccl2, Jun, Fos, Il4, Ccl7, Il13, and Socs1.
|
Western Blot Analysis
| Cell Line: |
IgE-mediated activated RBL-2H3 cells |
| Concentration: |
2.5, 5, 10 μg/mL |
| Incubation Time: |
1 h (pre-incubation prior to 15 min DNP-BSA stimulation) |
| Result: |
Dose-dependently reduced the levels of phosphorylated JNK, ERK, P38, and STAT6, while total protein levels of these proteins remained unchanged. Caused the most significant reduction in JNK and ERK phosphorylation at 10 μg/mL. Significantly reduced P38 and STAT6 phosphorylation at all tested doses. |
Cell Viability Assay
| Cell Line: |
murine macrophage-like RAW264.7 cells, murine immortalized microglial BV2 cells |
| Concentration: |
5, 10, 20, 40, 80, 160 μM |
| Incubation Time: |
24 h |
| Result: |
Did not reduce cell viability of RAW264.7 or BV2 cells. Decreased cell viability of RAW264.7 or BV2 cells relative to untreated controls at 160 μM. |
RT-PCR
| Cell Line: |
LPS-stimulated murine macrophage-like RAW264.7 cells |
| Concentration: |
10, 20, 40, 80 μM |
| Incubation Time: |
3 h pre-treatment, followed by 6 h LPS stimulation |
| Result: |
Reduced LPS-induced IL-1β, IL-6 and TNF-α mRNA expression dose-dependently. Significantly inhibited IL-1β, IL-6 and TNF-α mRNA expression at 40 and 80 μM. |
Cell Differentiation Assay
| Cell Line: |
mouse bone-derived mesenchymal stem cells (BMSCs) |
| Concentration: |
1, 5, 10 μM |
| Incubation Time: |
~21 days |
| Result: |
Induced chondrogenic differentiation of BMSCs in a concentration-dependent manner. Showed the highest relative Alcian blue staining fold change at 10 μM compared to control groups. |
Real Time qPCR
| Cell Line: |
MC3T3-E1 pre-osteoblast cells |
| Concentration: |
5 μM |
| Incubation Time: |
0 h, 6 h, 12 h, 24 h, 48 h, 3 days, 5 days, 8 days |
| Result: |
Inhibited Hivep3 (SHN3) mRNA expression in a time-dependent manner over 8 days. Promoted time-dependent increases in Alpl (early osteogenic marker) and Bglap (late osteogenic marker) mRNA expression. |
Western Blot Analysis
| Cell Line: |
MC3T3-E1 pre-osteoblast cells |
| Concentration: |
1, 5, 10 μM |
| Incubation Time: |
5 days |
| Result: |
Upregulated β-catenin, p-GSK-3β, and p-ERK1/2 protein levels in a concentration-dependent manner. Left NF-κB, total ERK1/2, and GSK-3β levels unchanged. Significantly inhibited SHN3 protein expression. |
Immunofluorescence
| Cell Line: |
mouse bone-derived mesenchymal stem cells (BMSCs) |
| Concentration: |
1, 5, 10 μM (5 days); 5 μM (3, 5, 8 days) |
| Incubation Time: |
3 days, 5 days, 8 days |
| Result: |
Significantly upregulated OCN and β-catenin protein levels in BMSCs, with 5 μM and 10 μM showing significant increases over control after 5 days. Showed time-dependent increases in OCN and β-catenin protein levels at 5 μM over 3, 5, and 8 days. |
|
体内研究 (In Vivo) |
Viridicatol (5 mg/kg;静脉注射;每日;6 周) 可通过增强成骨细胞活性、提升 BV/TV 及骨小梁数量来刺激骨形成,从而预防去卵巢小鼠的骨丢失。 Viridicatol (5 mg/kg;静脉注射;每 2 天 1 次;共 14 天) 可通过增加骨折部位的骨痂体积、骨量以及软骨和骨组织面积来促进骨折愈合。 Free viridicatol (5 mg/kg;静脉注射;每 2 天 1 次;持续 4 周) 在 Col1a2oim/oim 成骨不全症小鼠模型中仅能轻微缓解骨丢失。 Viridicatol 经骨靶向纳米囊泡给药 (5 mg/kg;静脉注射;每 2 天 1 次;持续 4 周) 可显著减少 Col1a2oim/oim 成骨不全症小鼠模型的自发性骨折并提升骨体积分数。
| Animal Model: |
C57BL/6J (female, 10-week-old, bilateral ovariectomy-induced osteoporosis model) |
| Dosage: |
5 mg/kg |
| Administration: |
i.v.; daily; 6 weeks |
| Result: |
Increased femur BV/TV and Tb.N versus untreated OVX group. Increased 5th lumbar spine bone mass via Von Kossa staining. Elevated MS/BS, MAR and BFR/BS. Increased Ob.S/BS in 5th lumbar vertebrae and femur without altering N.Oc.S/BS. Caused no significant weight changes, deaths or organ abnormalities. |
| Animal Model: |
C57BL/6J (female, 8-week-old, closed transverse diaphyseal femur fracture model stabilized with an intramedullary needle) |
| Dosage: |
5 mg/kg |
| Administration: |
i.v.; every 2 days; 14 days |
| Result: |
Significantly increased callus volume and BV/TV at the fracture site by micro-CT. Increased cartilage and bone areas at the fracture site by Safranin O/Fast Green staining. Increased Ob.S/BS without affecting osteoclast parameters. |
| Animal Model: |
Col1a2oim/oim (male, 4-week-old, osteogenesis imperfecta genetic model) |
| Dosage: |
5 mg/kg |
| Administration: |
i.v.; every 2 days; 4 weeks |
| Result: |
Showed limited therapeutic effects on severe osteopenic phenotype and spontaneous fracture incidence versus bone-targeted nanovesicle viridicatol, but trended toward improved bone parameters versus PBS control. Significantly mitigated osteopenic phenotype, reduced spontaneous fractures, and increased femur BV/TV and Ob.S/BS versus PBS, free viridicatol and non-targeted nanovesicle controls. |
|